Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bristol-Myers Squibb
(NY:
BMY
)
50.91
+0.79 (+1.58%)
Official Closing Price
Updated: 7:00 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
23,035,276
Open
51.54
Bid (Size)
51.09 (1)
Ask (Size)
51.18 (15)
Prev. Close
50.12
Today's Range
50.71 - 52.16
52wk Range
39.35 - 58.46
Shares Outstanding
2,222,113,553
Dividend Yield
4.48%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
3 Surprisingly Underrated Stocks to Buy Right Now
Today 7:30 EDT
These stocks might look like bad picks. But appearances can be deceiving.
Via
The Motley Fool
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
September 27, 2024
From
Bristol Myers Squibb
Via
Business Wire
Performance
YTD
-3.51%
-3.51%
1 Month
+3.77%
+3.77%
3 Month
+22.59%
+22.59%
6 Month
-3.93%
-3.93%
1 Year
-12.44%
-12.44%
More News
Read More
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
September 27, 2024
Via
Benzinga
Exposures
Product Safety
Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting
September 27, 2024
From
Bristol Myers Squibb
Via
Business Wire
NYSE:BMY Shows Potential for a Breakout.
September 23, 2024
Via
Chartmill
14 Stocks Gain Momentum As August Inflation Comes In Below Expectations
September 27, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb' Cobenfy As New Class Of Treatment In More Than 3 Decades
September 27, 2024
Via
Benzinga
Exposures
Product Safety
Why Establishment Labs Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket
September 27, 2024
Via
Benzinga
What Analysts Are Saying About Bristol-Myers Squibb Stock
September 16, 2024
Via
Benzinga
Current Report: Bristol-Meyers Squibb (BMY)
September 16, 2024
Via
Talk Markets
Wall Street On Wait-And-Watch Mode Ahead Of Inflation Data, Bitcoin Holds Above 65.5K: Analyst Says Volatility Ahead Providing Better Entry Point Into Long-term Bull Market
September 27, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Bristol-Myers Squibb's Novel Schizophrenia Drug Wins FDA Approval; BMY Stock Signals Breakout
September 26, 2024
Via
Investor's Business Daily
Exposures
Product Safety
FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients
September 25, 2024
Via
Benzinga
Exposures
Product Safety
Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability
September 25, 2024
Via
Benzinga
Exposures
Product Safety
Analysts Think There's Still Time to Get in on Edgewise, Up 332%
September 25, 2024
Via
MarketBeat
10 Health Care Stocks With Whale Alerts In Today's Session
September 23, 2024
Via
Benzinga
Bristol-Myers Acquired Drug KarXT Poised For FDA Approval As First New Type Of Schizophrenia Treatment In 70 Years
September 20, 2024
Via
Benzinga
Exposures
Product Safety
Edgewise Catapults On Surprise Victory In Cardiomyopathy; Cytokinetics Shares Dip
September 19, 2024
Via
Investor's Business Daily
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
September 19, 2024
Via
Investor's Business Daily
Bristol Myers Squibb Presents Data For Multiple Sclerosis Drug Zeposia, Shows Long-Term Efficacy
September 18, 2024
Via
Benzinga
New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis
September 18, 2024
From
Bristol Myers Squibb
Via
Business Wire
3 High-Yield Dividend Stocks Down by More Than 39% to Buy Now and Hold at Least a Decade
September 16, 2024
Via
The Motley Fool
Merck Scores Two Key Victories With Keytruda In Women's Cancers
September 15, 2024
Via
Investor's Business Daily
Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® plus Yervoy® in Advanced Melanoma
September 15, 2024
From
Bristol Myers Squibb
Via
Business Wire
Got $200? 2 Healthcare Stocks to Buy and Hold Forever
September 14, 2024
Via
The Motley Fool
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.